Preparation of the Compounds, Their New Salt Forms, and Therapeutic Uses
The described method efficiently synthesizes substituted pyridine compounds and their dihydrochloride salts on a large scale by minimizing isolation steps and using mild conditions, addressing inefficiencies in existing synthetic routes and enhancing production suitability for pharmaceutical use.
Patent Information
- Application Number
- JP2021536184
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-12-24
- Filing Date
- 2019-12-24
- Publication Date
- 2024-11-20
- Estimated Expiration
- 2039-12-24
AI Technical Summary
Existing synthetic routes for substituted pyridine compounds are inefficient, requiring numerous steps, high or low temperatures, and chromatographic purifications, making large-scale production challenging and resource-intensive.
A method involving sequential reactions with o-tolylmagnesium chloride, N-methylpiperazine, and iodine, followed by treatment with 3,5-bis(trifluoromethyl)benzyl bromide and a base, allows for the synthesis of substituted pyridine compounds and their dihydrochloride salts without isolation of intermediates, using mild temperatures and simplified purifications, suitable for large-scale production.
The process achieves high yields and efficient production of substituted pyridine compounds and their dihydrochloride salts, suitable for pharmaceutical applications, with improved handling and stability properties.
Smart Images

Figure 0007587215000029 
Figure 0007587215000030 
Figure 0007587215000031
Abstract
Description
[Technical field]
[0001] Field The present invention relates to the synthesis of unique substituted pyridine compounds and / or their salt forms, as well as new salt forms and therapeutic uses thereof. [Background technology]
[0002] background U.S. Pat. No. 6,303,790 describes, inter alia, compounds having the following general formula: [ka] The synthesis of the substituted pyridine compounds of the formula:
[0003] These compounds exhibit antagonist activity at the neurokinin 1 (NK-1, substance P) receptor and may be useful in the treatment or prevention of certain central nervous system disorders. The synthetic routes to these substituted pyridines involve the incorporation and removal of protecting groups and the introduction of reactive functional groups into the substrates of the subsequent reactions. These additional steps reduce the overall efficiency and atom economy of the synthesis. Furthermore, purification procedures for the compounds and their intermediates often involve chromatographic steps.
[0004] European Patent No. 1394150 describes, inter alia, compounds of the general formula: [ka] This invention discloses the synthesis of phenyl substituted pyridine compounds of the formula:
[0005] The disclosed synthetic routes require multiple steps including palladium-catalyzed coupling of arylboronic acids to incorporate phenyl substituents, reactions at very high (130° C.) or very low (−78° C.) temperatures, and the use of protecting groups. The document also discloses that each intermediate is isolated by column chromatography, which is time and resource consuming. In general, the disclosed synthetic routes teach the synthesis of the target compounds and their intermediates on the milligram or gram scale, with each intermediate (and thus the target compound) being produced in moderate yields.
[0006] Prior art routes to these substituted pyridines typically utilize numerous synthetic steps and reaction conditions which, either alone or when considered together, pose obstacles to the synthesis of these compounds on a large scale.
[0007] Even if the obstacles of the process or route can be overcome, the form of the compound may be important or desirable for its manufacture into a product. The form of the compound may also be important or desirable for its usefulness as a product. For example, certain characteristics, such as processability, flowability, thermal stability, consistency, etc., may be desirable during the manufacturing process and can only be provided by certain compound forms. Furthermore, certain product characteristics, such as expiration date, color, efficacy, release rate, etc., may be desirable and can only be provided by certain compound forms. In this regard, certain compound forms may be more desirable than other compound forms when these characteristics are considered alone or together. Summary of the Invention [Problem to be solved by the invention]
[0008] The present invention is directed to providing more efficient routes for the preparation of unique substituted pyridine compounds that are amenable to bulk, large scale, and GMP processing. The present invention is also specifically directed to substituted pyridine compounds and / or unique salt forms thereof that demonstrate unique processing and therapeutic advantages, particularly for the preparation of intravenous formulations. [Means for solving the problem]
[0009] Summary of the Invention In one aspect, the present invention provides a compound of formula (1): [ka] or a salt thereof, comprising the steps of: a) Formula (2): [ka] The compound of formula (3): [ka] Sequentially treating with o-tolylmagnesium chloride, N-methylpiperazine and iodine under conditions sufficient to provide a compound of b) treating the compound of formula (3) from step a) with 3,5-bis(trifluoromethyl)benzyl bromide and a suitable base under conditions sufficient to provide a compound of formula (1); The present invention provides a method comprising:
[0010] As used herein, the term "sequential," when used in reference to a series of reagents, refers to the successive addition of recited reagents to a substrate in a manner such that the intended reaction of the added reagent is allowed to occur prior to the addition of the next recited reagent, and the reaction product is not isolated until after the last recited reagent has been added to the reaction.
[0011] In another aspect, the present invention provides a compound of formula (1): [ka] 1. A process for preparing the dihydrochloride salt of a compound of a) Formula (2): [ka] The compound of formula (3): [ka] Sequentially treating with o-tolylmagnesium chloride, N-methylpiperazine and iodine under conditions sufficient to provide a compound of b) treating the compound of formula (3) from step a) with 3,5-bis(trifluoromethyl)benzyl bromide and a suitable base under conditions sufficient to provide a compound of formula (1); and c) treating the compound of formula (1) obtained from step b) with a solution of hydrochloric acid in diethyl ether under conditions sufficient to obtain the dihydrochloride salt of the compound of formula (1); The present invention provides a method comprising:
[0012] In yet another aspect, the present invention relates to a compound of formula (1) produced by the above-mentioned aspect: [ka] or a salt thereof.
[0013] In yet another aspect, the present invention relates to a compound of formula (1): [ka] The dihydrochloride salt of the compound of formula (I) is provided. [Brief description of the drawings]
[0014] [Figure 1] FT-IR spectrum of compound (1) 2HCl salt. [Diagram 2] H-NMR spectrum of compound (1) free base (400 MHz, DMSO-d6) (20.5 mg) (relative to DMSO-d6 at 2.50 ppm). [Diagram 3] C NMR data for compound (1) free base (150 MHz, DMSO-d) (20.5 mg) (relative to DMSO-d at 39.57 ppm). [Figure 4] H-NMR spectrum of compound (1) 2HCl salt (600 MHz, DMSO-d6) (200 mg) (relative to DMSO-d6 at 2.50 ppm). [Diagram 5] C NMR data for compound (1) salt (150 MHz, DMSO-d) (200 mg) (relative to DMSO-d at 39.57 ppm). [Figure 6] Mass spectrum of compound (1) 2HCl salt. [Figure 7] XRPD of compound (1) 2HCl salt. [Figure 8] DSC of compound (1) 2HCl salt. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0015] Detailed Description of the Invention Throughout this specification and the claims that follow, unless the context requires otherwise, it will be understood that the language "comprise," as well as variations such as "comprises" and "comprising," imply the inclusion of a stated integer or step, or group of integers or steps, but not the exclusion of any other integers or steps, or group of integers or steps.
[0016] The present invention is based on the unexpected discovery that compounds of formula (1) and / or salts thereof can be efficiently prepared in kilogram-scale quantities with good to high yields. The process disclosed herein has been shown to be amenable to scale-up, allowing the production of compounds of formula (1) and / or salts thereof on a large scale in an efficient and safe manner suitable for GMP conditions for the production of materials suitable for pharmaceutical administration. The efficiency of the process is improved by employing steps that minimize the use of protecting groups on reagents and substrates, and can be carried out without the use of very high or very low temperatures, as shown in the accompanying examples.
[0017] The present inventors have discovered that the compound represented by formula (3): [ka] The compound of formula (2): [ka] can be obtained by sequential treatment of the compound of formula (2) with o-tolylmagnesium chloride, N-methylpiperazine and iodine. The inventors have also found that the intermediate obtained from the treatment of the compound of formula (2) with o-tolylmagnesium chloride and N-methylpiperazine does not require isolation before the next reaction step, and that a simple purification procedure to remove reaction impurities can provide the compound or intermediate of sufficient purity for the next reaction.
[0018] As used herein, the term "isolated" when referring to a compound or intermediate refers to the compound or intermediate being physically removed from any other compounds, solvents or substances. References to a "purification" step as used herein are distinct from an "isolation" step, the completion of which only provides the compound or intermediate in isolated form, the completion of which provides the compound or intermediate in the presence of at least one other compound, solvent or other substance. For example, a purification step may include steps such as washing with aqueous or organic solvents, acid-base extraction, simple filtration or solvent exchange. This should be contrasted with chromatographic separation steps, such as flash column chromatography, liquid chromatography and other preparative chromatographic methods, which provide the compound in substantially pure form.
[0019] Thus, in certain embodiments, the process of the invention is carried out on a multi-gram scale. In certain embodiments, the process of the invention is carried out on a kilogram scale. In certain embodiments, the process of the invention is carried out on a multi-kilogram scale.
[0020] In one embodiment, the method comprises treating an amide of formula (2) with o-tolylmagnesium chloride under conditions to produce an intermediate of formula (5a), which may be tautomerized in situ to a compound of formula (5b): [ka]
[0021] In certain embodiments, the reaction between the amide of formula (2) and o-tolylmagnesium chloride may be carried out in tetrahydrofuran (THF). In certain embodiments, the THF is anhydrous. In certain embodiments, the reaction is carried out at a temperature range of -5°C to 5°C, such as about -5°C, -4°C, -3°C, -2°C, -1°C, 0°C, 1°C, 2°C, 3°C, 4°C, or 5°C. In one embodiment, the reaction between the amide of formula (2) and o-tolylmagnesium chloride is carried out at a temperature of about 0°C. In one embodiment, the reaction between the amide of formula (2) and o-tolylmagnesium chloride is carried out in anhydrous THF at a temperature of about 0°C.
[0022] In certain embodiments, the reaction between the amide of formula (2) and o-tolylmagnesium chloride is carried out by adding the amide of formula (2) to a solution of o-tolylmagnesium chloride. In certain embodiments, the solution of o-tolylmagnesium chloride is a solution in THF. In certain embodiments, the solution of o-tolylmagnesium chloride is a solution in THF at a concentration of 1 mol / L. In certain embodiments, the amide of formula (2) is added dropwise to the solution of o-tolylmagnesium chloride. In certain embodiments, the amide of formula (2) is added dropwise to the solution of o-tolylmagnesium chloride at a temperature of about 0° C. In certain embodiments, the amide of formula (2) is added dropwise to the solution of o-tolylmagnesium chloride at a temperature of about 0° C. over a period of about 1 hour. In certain embodiments, the reaction between the amide of formula (2) and o-tolylmagnesium chloride is stirred for at least 1 hour. In certain embodiments, the reaction between the amide of formula (2) and o-tolylmagnesium chloride is stirred at a temperature of about 20° C. for at least 1 hour.
[0023] The reaction between the amide of formula (2) and o-tolylmagnesium chloride may be monitored by high performance liquid chromatography (HPLC). In certain embodiments, the reaction between the amide of formula (2) and o-tolylmagnesium chloride is stirred at a temperature of about 20° C. until HPLC analysis indicates that the amide of formula (2) is present in an amount of about 8% or less of the reaction mixture. In certain embodiments, when HPLC analysis of the reaction between the amide of formula (2) and o-tolylmagnesium chloride indicates that the amide of formula (2) is present in an amount of more than about 8%, an additional aliquot of o-tolylmagnesium chloride as a solution in THF is added dropwise to the reaction mixture.
[0024] In certain embodiments, the reaction between the amide of formula (2) and o-tolylmagnesium chloride is diluted with ethyl acetate when HPLC analysis indicates that the amide of formula (2) is present in an amount of about 8% or less of the reaction mixture. In certain embodiments, the reaction between the amide of formula (2) and o-tolylmagnesium chloride produces a compound of formula (5a) and its tautomeric form (5b). Given the tautomeric relationship between the compound of formula (5a) and the compound of formula (5b), any reference to a compound of formula (5a) shall be taken to mean the compound of formula (5a) and its tautomeric form (5b), if present, unless otherwise indicated.
[0025] As can be appreciated, the compounds of formula (5a) and, if present, their tautomeric forms of formula (5b) are not isolated from the reaction mixture in which they are formed, but are directly subjected to the next reaction.
[0026] The compound of formula (5a) is then reacted with the compound of formula (4): [ka] is subjected to reaction with N-methylpiperazine under conditions to produce a compound of the formula:
[0027] In certain embodiments, N-methylpiperazine is added to the solution of formula (5a). In certain embodiments, the compound of formula (5a) is treated with about 5 molar equivalents of N-methylpiperazine. In certain embodiments, the reaction mixture of the compound of formula (5a) and N-methylpiperazine is stirred at a temperature range of about 15°C to 25°C, such as about 15°C, 16°C, 17°C, 18°C, 19°C, 20°C, 21°C, 22°C, 23°C, 24°C, or 25°C. In one embodiment, the reaction of the compound of formula (5a) and N-methylpiperazine is stirred at a temperature of about 20°C. In certain embodiments, the reaction of the compound of formula (5a) and N-methylpiperazine is stirred at about 20°C for about 10 hours. In certain embodiments, the reaction between the compound of formula (5a) and N-methylpiperazine is monitored by HPLC. In certain embodiments, the reaction between the compound of formula (5a) and N-methylpiperazine is stirred at a temperature of 20° C. until HPLC analysis indicates that the compound of formula (5a) (excluding the tautomer formula (5b)) is present in an amount of about 2% or less of the reaction mixture. In certain embodiments, the reaction between the compound of formula (5a) and N-methylpiperazine produces a compound of formula (4) in solution.
[0028] In certain embodiments, the reaction mixture containing the compound of formula (4) formed between the compound of formula (5a) and N-methylpiperazine is cooled to a temperature range of about -5°C to 5°C when HPLC analysis indicates that the compound of formula (5a) is present in an amount of about 2% or less of the reaction mixture. In certain embodiments, the temperature is about -5°C, -4°C, -3°C, -2°C, -1°C, 0°C, 1°C, 2°C, 3°C, 4°C, or 5°C. In certain embodiments, the reaction mixture containing the compound of formula (4) is diluted with an aqueous solution of acetic acid. In certain embodiments, the aqueous solution of acetic acid has a concentration of about 7%. In certain embodiments, the aqueous solution of acetic acid is added to the solution of formula (4) such that the temperature of the resulting solution does not exceed about 20°C. In certain embodiments, the solution of formula (4) has a pH of about 8 after the addition of the solution of acetic acid.
[0029] The compound of formula (4) is not isolated by chromatography prior to any further reaction, but may be subjected to purification prior to any further reaction. In certain embodiments, the compound of formula (4) is purified by partition between an aqueous solvent and an organic solvent. In certain embodiments, the compound of formula (4) is purified by extraction from the aqueous phase into an organic phase. In certain embodiments, the aqueous solution is a solution in which the compound of formula (4) is dissolved and may include an added acetic acid solution. In certain embodiments, the organic solvent is dichloromethane. In certain embodiments, the compound of formula (4) is purified by extraction from the aqueous phase into dichloromethane. In certain embodiments, the compound of formula (4) is purified by multiple extractions of the aqueous phase with dichloromethane. In certain embodiments, the aqueous phase is extracted at least 2, 3 or 4 times with dichloromethane. In certain embodiments, the dichloromethane extracts containing the compound of formula (4) are combined, dried with a drying agent, and concentrated. In certain embodiments, the drying agent is anhydrous sodium sulfate. In certain embodiments, the compound of formula (4) in dichloromethane is purified by solvent exchange. In certain embodiments, the compound of formula (4) in dichloromethane is purified by solvent exchange with THF. In certain embodiments, the dichloromethane solution of the compound of formula (4) is converted to a solution in THF by adding an aliquot of THF and then concentrating the solution under vacuum until the dichloromethane is removed and only THF remains as the solvent. It will be appreciated that the compound of formula (4) is not isolated prior to any further reaction.
[0030] The compound of formula (4) is then reacted with the compound of formula (3): [ka] is subjected to reaction with iodine under conditions to produce a compound of the formula:
[0031] In certain embodiments, the compound of formula (4) in a solution of THF is subjected to reaction with iodine to produce a compound of formula (3). In certain embodiments, the solution of formula (4) in THF is cooled to a temperature ranging from about -5°C to about 5°C, such as -5°C, -4°C, -3°C, -2°C, -1°C, 0°C, 1°C, 2°C, 3°C, 4°C, or 5°C, prior to reaction with iodine. In certain embodiments, iodine is in a solution of THF. In certain embodiments, the solution of iodine in THF is cooled to a temperature ranging from about -5°C to about 5°C, such as -5°C, -4°C, -3°C, -2°C, -1°C, 0°C, 1°C, 2°C, 3°C, 4°C, or 5°C, prior to reaction with the compound of formula (4). In certain embodiments, a cooled solution of iodine is added to a cooled solution of the compound of formula (4). In certain embodiments, a cooled solution of iodine is added in a dropwise manner to a cooled solution of the compound of Formula (4).
[0032] In certain embodiments, the reaction mixture of the compound of formula (4) and iodine in THF is heated to a temperature ranging from about 15° C. to about 25° C., such as 15° C., 16° C., 17° C., 18° C., 19° C., 20° C., 21° C., 22° C., 23° C., 24° C., or 25° C. In one embodiment, the reaction mixture is heated to about 20° C. In certain embodiments, the reaction mixture of the compound of formula (4) and iodine is stirred at a temperature of about 20° C. for about 15 hours.
[0033] In certain embodiments, the reaction of the compound of formula (4) with iodine is monitored by HPLC. In certain embodiments, the reaction of the compound of formula (4) with iodine is stirred until HPLC analysis indicates that the reaction contains 2% or less of the compound of formula (4) present. In certain embodiments, stirring the reaction of the compound of formula (4) with iodine for more than 15 hours will result in a reaction mixture containing 2% or less of the compound of formula (4) by HPLC analysis. If 2% or less of the compound of formula (4) is present after 15 hours, the reaction mixture is cooled to a temperature in the range of about -5°C to about 5°C, such as -5°C, -4°C, -3°C, -2°C, -1°C, 0°C, 1°C, 2°C, 3°C, 4°C, or 5°C, and an aqueous solution of magnesium hydroxide and acetic acid is added to the reaction mixture. In certain embodiments, 0.2 molar equivalents of magnesium hydroxide are added. In certain embodiments, the acetic acid is present in the aqueous solution at a concentration of about 10% v / v. In certain embodiments, the reaction mixture containing the compound of formula (4), iodine, magnesium hydroxide, and acetic acid is heated to a temperature ranging from about 15°C to about 25°C, such as 15°C, 16°C, 17°C, 18°C, 19°C, 20°C, 21°C, 22°C, 23°C, 24°C, or 25°C, and stirred for at least 15 hours. In certain embodiments, the reaction mixture contains 2% or less of the compound of formula (4) by HPLC analysis. In certain embodiments, the reaction mixture contains the compound of formula (3).
[0034] In certain embodiments, the compound of formula (3) is in a solution of THF, the solution further comprising iodine, magnesium hydroxide, and acetic acid. In certain embodiments, the compound of formula (3) is purified prior to the next reaction step. In certain embodiments, purification of the compound of formula (3) requires cooling of the reaction mixture to a temperature in the range of about 0°C to about 10°C, such as 0°C, 1°C, 2°C, 3°C, 4°C, 5°C, 6°C, 7°C, 8°C, 9°C, or 10°C, before an aqueous solution of sodium thiosulfate (Na2S2O3) is added. In certain embodiments, the concentration of the aqueous solution of sodium thiosulfate is about 10%. In certain embodiments, the reaction mixture is held at a temperature of 10°C or less during the addition of the aqueous solution of sodium thiosulfate.
[0035] In certain embodiments, the compound of formula (3) in a solution of THF and aqueous sodium thiosulfate is subjected to vacuum distillation to remove any THF present. In certain embodiments, the vacuum distillation of THF from the reaction mixture containing the compound of formula (3) is carried out at a temperature of 40° C. or less.
[0036] In certain embodiments, the solution containing the compound of formula (3) is cooled to a temperature in the range of about 0° C. to about 10° C., such as 0° C., 1° C., 2° C., 3° C., 4° C., 5° C., 6° C., 7° C., 8° C., 9° C., or 10° C., before the aqueous solution of hydrochloric acid is added.
[0037] In certain embodiments, the concentration of the aqueous solution of hydrochloric acid is about 2 mol / L. In certain embodiments, the solution containing the compound of formula (3) is adjusted to a pH of between about 1 and about 2 as a result of the addition of the aqueous solution of hydrochloric acid. In certain embodiments, the solution containing the compound of formula (3) is maintained at a temperature of 10° C. or less during the addition of the aqueous solution of hydrochloric acid. In certain embodiments, the acidified aqueous solution is purified by extraction into ethyl acetate (EtOAc).
[0038] In certain embodiments, the acidified aqueous solution containing the compound of formula (3) is adjusted to a pH between about 8 and about 9 after extraction into ethyl acetate. In certain embodiments, an aqueous solution of sodium hydroxide (NaOH) is used to adjust the pH of the solution of formula (3). In certain embodiments, the aqueous solution of NaOH has a concentration of about 2 mol / L. In certain embodiments, the solution containing the compound of formula (3) is maintained at a temperature of 10° C. or less during the addition of the aqueous solution of NaOH.
[0039] In certain embodiments, a solution of Formula (3) at a pH between about 8 and about 9 is purified by phase extraction. In certain embodiments, an aqueous solution of Formula (3) is extracted into dichloromethane and the combined dichloromethane extracts are dried with sodium sulfate (Na2SO4). In certain embodiments, the volume of the solution containing the compound of Formula (3) is reduced under vacuum. In certain embodiments, the solution of Formula (3) is at a concentration of about 20 mL / g compound.
[0040] The present inventors have found that the intermediate compound of formula (3) does not require isolation for the next reaction to be carried out and can be satisfactorily purified by a solvent exchange procedure.
[0041] In certain embodiments, the dichloromethane solution of the compound of formula (3) is cooled to a temperature ranging from about 15°C to about 25°C, such as 15°C, 16°C, 17°C, 18°C, 19°C, 20°C, 21°C, 22°C, 23°C, 24°C, or 25°C, and then subjected to a solvent exchange with methyl tert-butyl ether (MTBE). In certain embodiments, MTBE is added to the cooled solution of formula (3). In certain embodiments, MTBE is added to the cooled solution of formula (3) over a period of about 20 minutes, about 30 minutes, or about 40 minutes. In certain embodiments, the volume of the solution of formula (3) in dichloromethane and MTBE is reduced under vacuum at a temperature of 40°C or less. In certain embodiments, the solvent exchange procedure with MTBE is repeated until the solution of formula (3) contains dichloromethane at a concentration of 3% or less when analyzed by gas chromatography. In certain embodiments, the solvent exchange procedure is repeated at least two times.
[0042] In certain embodiments, a suspension of the compound of formula (3) in MTBE is granulated at a temperature ranging from about 15° C. to about 25° C., such as 15° C., 16° C., 17° C., 18° C., 19° C., 20° C., 21° C., 22° C., 23° C., 24° C., or 25° C., for at least 1 hour. In certain embodiments, the granulated compound of formula (3) is isolated by filtration. In certain embodiments, the compound of formula (3) is washed with aliquots of MTBE. In certain embodiments, the compound of formula (3) is washed with at least 5 aliquots of MTBE. In certain embodiments, the washed compound of formula (3) is dried under vacuum at a temperature ranging from about 30° C. to about 40° C., such as 30° C., 31° C., 32° C., 33° C., 34° C., 35° C., 36° C., 37° C., 38° C., 39° C., or 40° C. In certain embodiments, the isolated compound of formula (3) is a solid. In certain embodiments, the isolated compound of formula (3) is an off-white solid. In certain embodiments, the isolated compound of formula (3) is a brown solid. In certain embodiments, the isolated compound of formula (3) is an off-white to brown solid. In certain embodiments, the compound of formula (3) may be subjected to a further isolation step.
[0043] The compound of formula (3) is then reacted with 3,5-bis(trifluoromethyl)benzyl bromide and a base to give the compound of formula (1): [ka] The compound is produced.
[0044] In a particular embodiment, the base used is potassium tert-butoxide (KOtBu).
[0045] In certain embodiments, the isolated compound of formula (3) is dissolved in THF. In certain embodiments, the THF is anhydrous. In certain embodiments, the compound of formula (3) is dissolved in THF under an inert atmosphere. In certain embodiments, the inert atmosphere is a nitrogen atmosphere. In certain embodiments, the isolated compound of formula (3) is dissolved in THF under nitrogen at a temperature ranging from about -2.5°C to about 7.5°C, such as -2.5°C, -1.5°C, -1°, 0°C, 0.5°C, 1.5°C, 2.5°C, 3.5°C, 4.5°C, 5°C, 5.5°C, 6.5°C, or 7.5°C.
[0046] In certain embodiments, KOtBu is added to a compound of formula (3) dissolved in THF. In certain embodiments, the mixture of KOtBu and a compound of formula (3) is stirred for at least 15 minutes.
[0047] In certain embodiments, 3,5-bis(trifluoromethyl)benzyl bromide is added to a solution of KOtBu and the compound of formula (3). In certain embodiments, 3,5-bis(trifluoromethyl)benzyl bromide is added dropwise over a period of at least 30 minutes at a temperature of 5° C. or less. In certain embodiments, the mixture of 3,5-bis(trifluoromethyl)benzyl bromide, KOtBu, and the compound of formula (3) is stirred for at least 30 minutes at a temperature of 5° C. or less. In certain embodiments, the reaction of formula (3) is stirred until analysis by HPLC indicates that the compound of formula (3) is present at a concentration of 2% or less.
[0048] In certain embodiments, the reaction mixture containing 2% or less of Formula (3) is diluted with water. In certain embodiments, the reaction mixture is at a temperature of 20° C. or less when diluted with water. In certain embodiments, the diluted reaction mixture is acidified to a pH between about 1 and about 2. In certain embodiments, the diluted reaction mixture is acidified with an aqueous solution of hydrochloric acid. In certain embodiments, the aqueous solution of hydrochloric acid has a concentration of about 2 mol / L. In certain embodiments, the acidified reaction mixture is washed with n-heptane.
[0049] In certain embodiments, the acidified reaction mixture is adjusted to a pH between about 8 and about 9. In certain embodiments, an aqueous solution of NaOH is used to adjust the pH of the acidified reaction mixture. In certain embodiments, the aqueous solution of NaOH has a concentration of about 2 mol / L. In certain embodiments, the acidified reaction mixture is held at a temperature of about 20° C. or less when the pH is adjusted with the aqueous solution of NaOH. In certain embodiments, the pH adjusted reaction mixture is extracted into dichloromethane. In certain embodiments, the reaction mixture is extracted into dichloromethane at least three times. In certain embodiments, the combined dichloromethane extracts are dried with sodium sulfate. In certain embodiments, the dried dichloromethane extracts are circulated through a plug of silica gel. In certain embodiments, the dried dichloromethane extracts are filtered through a plug of silica gel at least three times. In certain embodiments, the plug of silica gel is washed with dichloromethane. In certain embodiments, the silica gel is silica gel 60.
[0050] Although the compound of formula (1) is highly soluble or soluble in many solvents, the inventors have found that the compound of formula (1) is difficult to handle on a large scale. Without wishing to be bound by theory, the inventors believe that this may be due to the fact that the compound of formula (1) is amorphous and hydrophobic. There is also no tendency for the compound of formula (1) as a free base to form crystalline material, and it does not show clear thermal events and diffraction peaks. This is undesirable because process times may be increased, which may be exacerbated by greater material loss during processing.
[0051] In this regard, to further explore possibilities for improving the handling of the compound during the manufacturing process and the properties of the final product, an analysis of the interaction of the compound of formula (1) with various counter ions in various solvents was carried out.
[0052] Those skilled in the art will understand that such implementation is not straightforward or obvious, as many factors must be considered to justify these combinations as viable test options. Furthermore, there is a need to limit the number of combinations so that the analysis is manageable. For example, the physical properties of the compound, such as pKa, pH, molecular weight, melting point, specific gravity, solubility, polarity, and appearance, and chemical properties, such as degradation profile, reactivity, stability, and isomerism, will need to be considered not only for handling during the process steps, but also to ensure that the compound remains active when formed into a product. Furthermore, the salt form will also need to be analyzed for its pharmacokinetic properties. Even if a particular salt form may provide desired properties in one aspect, such as in a manufacturing process, its selection must be evaluated in light of other properties (e.g., pharmacokinetic properties). To further complicate this point, the compound of formula (1) has three possible acidic sites. Therefore, it is not straightforward to improve and predict the important physicochemical properties of formula (1) by salt formation.
[0053] The inventors have found that the unique dihydrochloride salt form of the compound of formula (1) exhibits desirable properties, particularly for intravenous (IV) formulations. The objective was to explore how some of the key physicochemical properties of the compound of formula (1) (e.g., solubility, stability, bioavailability, etc.) could be improved. In this regard, the inventors first screened based on criteria such as crystallinity, polymorphic behavior, solubility (particularly for use in potential aqueous IV formulations). For example, the inventors found that formates, acetates, phosphates, and sulfates had no tendency to form crystalline material in any of the solvents used, and on this basis did not consider them. Although it was initially thought that citrates, tartrates, hydrobromides, and methanesulfonates produced the best crystalline forms and could be suitable candidates, some of these salt forms do not appear to be stable and exhibit some degradation and / or polymorphism over time. Such salts are also unstable at usable pHs and convert to amorphous gels. Furthermore, some of these salt forms begin to decompose upon melting, suggesting that processing these salts may be challenging.
[0054] Regarding the hydrochloride salt formation of the compound of formula (1), the inventors hypothesized that the compound of formula (1) could theoretically form three salt forms: monohydrochloride, dihydrochloride and trihydrochloride. When this study was actually carried out, it was found that the monohydrochloride salt further produced a viscous solid that was difficult to process and showed a relatively low tendency to form crystalline material. In comparison, the trihydrochloride salt is easier to process, but is hygroscopic and requires more lengthy and expensive steps, which is undesirable. Also, the trihydrochloride salt form is more acidic than either the monohydrochloride or dihydrochloride salt forms, which would induce local irritation if administered to a subject. In contrast, the dihydrochloride salt was surprisingly found to be ideal in terms of manageable processing, stability and therapeutic outcome, even if it was produced in an amorphous form. In certain embodiments, the dihydrochloride salt is produced substantially free of either the monohydrochloride or trihydrochloride salt, for example with a purity of more than 95%.
[0055] Thus, in one embodiment, the present invention also provides a compound of formula (1): [ka] 1. A process for preparing the dihydrochloride salt of a compound of a) Formula (2): [ka] The compound of formula (3): [ka] Sequentially treating with o-tolylmagnesium chloride, N-methylpiperazine and iodine under conditions sufficient to provide a compound of b) treating the compound of formula (3) from step a) with 3,5-bis(trifluoromethyl)benzyl bromide and a suitable base under conditions sufficient to provide a compound of formula (1); c) treating the compound of formula (1) with a solution of hydrochloric acid in diethyl ether under conditions sufficient to provide the dihydrochloride salt of the compound of formula (1); The present invention provides a method comprising:
[0056] The inventors have found that the compound of formula (1) can be converted to a dihydrochloride salt. The inventors have further found that the compound of formula (1) can be converted to a dihydrochloride salt without isolating the free base of the compound of formula (1), although in some embodiments, the compound of formula (1) can be isolated prior to conversion to the dihydrochloride salt.
[0057] In certain embodiments, the combined dichloromethane extract containing the compound of formula (1) obtained from filtration through silica gel is concentrated under vacuum at a temperature of 40° C. or less. In certain embodiments, the dichloromethane extract is concentrated to provide the compound of formula (1) in a solution of dichloromethane, wherein the solution has a concentration of formula (1) of about 10 mL / g. In certain embodiments, the solution of formula (1) in dichloromethane is cooled to a temperature ranging from about −5° C. to about 5° C., such as −5° C., −4° C., −3° C., −2° C., −1° C., 0° C., 1° C., 2° C., 3° C., 4° C., or 5° C. In certain embodiments, an aqueous solution of hydrochloric acid is added to the cooled solution of formula (1). In certain embodiments, an aqueous solution of hydrochloric acid is added dropwise to the cooled solution of formula (1). In certain embodiments, the cooled solution of formula (1) is maintained at a temperature in the range of about -5°C to about 5°C, such as -5°C, -4°C, -3°C, -2°C, -1°C, 0°C, 1°C, 2°C, 3°C, 4°C, or 5°C, during the addition of the aqueous solution of hydrochloric acid. In certain embodiments, the concentration of the aqueous solution of hydrochloric acid is about 2 mol / L.
[0058] In certain embodiments, a suspension of the dihydrochloride salt of formula (1) is obtained after the addition of hydrochloric acid. In certain embodiments, the suspension of the dihydrochloride salt of formula (1) is stirred for about 1 hour at a temperature ranging from about -5°C to about 5°C, such as -5°C, -4°C, -3°C, -2°C, -1°C, 0°C, 1°C, 2°C, 3°C, 4°C, or 5°C. In certain embodiments, MTBE is added to the suspension of the dihydrochloride salt of formula (1) at a temperature of about 15°C to about 25°C, such as 15°C, 16°C, 17°C, 18°C, 19°C, 20°C, 21°C, 22°C, 23°C, 24°C, or 25°C. In certain embodiments, MTBE is added to the suspension of the dihydrochloride salt of formula (1) over a period of about 20 minutes, about 30 minutes, or about 40 minutes. In certain embodiments, the volume of the solution of formula (1) suspended in dichloromethane and MTBE is reduced under vacuum at a temperature of 40°C or less. In certain embodiments, the solvent exchange procedure with MTBE is repeated until the solution of Formula (1) contains a concentration of dichloromethane of 3% or less when analyzed by gas chromatography, hi certain embodiments, the solvent exchange procedure is repeated at least two times.
[0059] In certain embodiments, the suspension containing the dihydrochloride salt of Formula (1) is granulated at a temperature of about 15° C. to about 25° C., such as 15° C., 16° C., 17° C., 18° C., 19° C., 20° C., 21° C., 22° C., 23° C., 24° C., or 25° C., for at least 1 hour.
[0060] In certain embodiments, a compound of formula (1) is produced. In other embodiments, a compound of formula (1) or a salt thereof is produced. In this regard, the salt may be a pharma- ceutically acceptable salt.
[0061] In yet another aspect, the present invention relates to a compound of formula (1): [ka] The dihydrochloride salt of the compound of formula (I) is provided.
[0062] In particular embodiments, it is desirable to produce the dihydrochloride salt substantially free of the monohydrochloride or trihydrochloride salts, and in this regard, the inventors have found that this can be achieved with an acid:base molar ratio (at 25° C.) of about 1.8 to 1.9:1, such as ratios of 1.80:1, 1.81:1, 1.82:1, 1.83:1, 1.84:1, 1.85:1, 1.86:1, 1.87:1, 1.88:1, 1.89:1, and about 1.90:1.
[0063] The reference in this specification to any prior publication (or information derived therefrom) or any known matter is not, and should not be taken as, an admission or any form of suggestion that that prior publication (or information derived therefrom) or known matter forms part of the common general knowledge in the field to which this specification is intended to pertain.
[0064] The following examples are illustrative of the present invention and should not be construed as limiting thereof.
[0065] The following reactions may be carried out on milligram, gram or kilogram scale. [ka]
[0066] Synthesis of N-methyl-6-(4-methylpiperazin-1-yl)-4-(o-tolyl)nicotinamide (3) 1. 6-Chloro-N-methylnicotinamide is dissolved in anhydrous THF (20 vol / g) and stirred for at least 3 min at 20±5° C. (target 20° C.) under N2 (colorless, slightly hazy solution). 2. A 1M solution of o-tolylmagnesium chloride in THF (2.5 eq.) is cooled to 0±5° C. (target 0° C.) and stirred under N2 (clear dark brown / black solution). 3. Add the 6-chloro-N-methylnicotinamide solution dropwise to the o-tolylmagnesium chloride solution at 0±5° C. (target 0° C. for at least 60 minutes). 4. Warm the reaction to 20±5° C. (target 20° C.) and stir for at least 1 hour until HPLC indicates no more than 8% 6-chloro-N-methylnicotinamide is present at 260 nm (dark green / brown solution). If the HPLC details cannot be met, slowly add and stir an additional charge of 1M o-tolylmagnesium chloride in THF at 0±5° C. (target 0° C.) until the HPLC details are met. 5. Cool the reaction to 0±5° C. (target 5° C.) and add EtOAc (6.6 g / g) at below 10° C. (target 5° C.). 6. Warm the mixture to 20±5° C. (target 20° C.) and stir for at least 40 minutes. 7. N-methylpiperazine (5 eq) is added in one portion at 20±5° C. (target 20° C.) and the reaction is stirred for at least 10 hours until HPLC indicates less than 2% of intermediate 5a is present at 260 nm and 330 nm. 8. Cool the reaction mixture to 5±5° C. (target 5° C.) and add 7% AcOH (20 vol / g) in water at 15±5° C. at a rate such that the internal temperature remains below 20° C. (approximately pH 8). 9. The phases are separated and the aqueous phase is back extracted with DCM (4×10 vol / g) (dark brown / red-orange / yellow solution). 10. The combined organic phase is dried over anhydrous Na2SO4 (4.0 g / g), filtered and washed with DCM (2 x 5 vol / g). 11. The solution is concentrated under vacuum via solvent exchange with THF to approximately 20 mL / g of 6-chloro-N-methylnicotinamide at up to 40° C. 12. Cool the intermediate 2 solution to 0±5°C (target 0°C). 13. I2 (1.5 equiv.) is dissolved in anhydrous THF (10 vol / g) under N2 and cooled to 0±5° C. (target 0° C.). 14. Add the iodine solution dropwise to the intermediate 2 solution at 0±5° C. (target 0° C.). 15. Warm the reaction to 20±5° C. (target 20° C.) and stir for at least 15 hours until HPLC indicates less than 2% of intermediate 2 is present at 330 nm. If the HPLC details cannot be met, add magnesium hydroxide (0.2 eq) and 10% v / v acetic acid in water (1.5 vol / g) to the reaction mixture at 0±5° C. (target 0° C.), warm to 20±5° C. (target 20° C.) and stir for at least a further 15 hours until the HPLC details are met. 16. Cool the reaction to 5±5°C (target 5°C) and add 10% Na2S2O3 in water (10 vol / g) at a rate such that the internal temperature remains below 10°C. 17. THF is distilled under vacuum below 40°C. 18. Cool the solution to 5±5°C (target 5°C) and add 2M HCl (approximately 3.5 vol / g) to adjust the pH to 1-2 (target pH 1.5) at <10°C. 19. Extract the aqueous phase with EtOAc (3×30 vol / g). 20. Cool the aqueous phase to 5±5°C (target 5°C) and add 2M NaOH (approximately 4 vol / g) to adjust the pH to 8-9 (target pH 8.5) at up to 10°C. 21. The aqueous phase is extracted with DCM (3×30 vol / g) and the combined organic phases are dried over anhydrous Na 2 SO 4 (2 g / g), filtered and washed with DCM (2×5 vol / g). 22. Concentrate the solution under vacuum at 40° C. until the volume is reduced to approximately 20 mL / g. 23. A solvent exchange with MTBE (20 vol / g) is performed by cooling the solution to 20±5° C. (target 20° C.) and slowly adding MTBE over 20-40 min (target 30 min). The solution is concentrated under vacuum below 40° C. until the volume is reduced to approximately 20 mL / g. 24. Repeat the solvent switch with MTBE (20 vol / g) until GC shows that the DCM content is less than 3%. 25. Granulate the resulting suspension at 20±5°C (target 20°C) for at least 1 hour. 26. The product is filtered, washed with MTBE (5×6 mL / g) and dried under vacuum at 35±5° C. to afford the compound of formula (3) as an off-white to brown solid in 64% yield. [ka]
[0067] Synthesis of N-{[3,5-bis(trifluoromethyl)phenyl]methyl}-N-methyl-4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinecarboxamide (1) 1. Intermediate 3 (1 eq.) is dissolved in anhydrous THF (10 vol / g) at 20±5° C. (target 20° C.) under N2 and cooled to −2.5±7.5° C. (target 0° C.). 2. Add potassium tert-butoxide (1.5 eq.) below 5° C. and stir for at least 15 minutes. 3. 3,5-Bis(trifluoromethyl)benzyl bromide (1.2 eq.) is added dropwise at or below 5° C. over at least 30 min. 4. The reaction mixture is stirred at or below 5° C. for at least 30 minutes until HPLC indicates that less than 2% of intermediate 3 is present at 260 and 300 nm. 5. Once the reaction is complete, add water (10 vol / g) below 20°C. 6. Acidify the reaction mixture to pH 1-2 (target pH 1.5) using 2M HCl (approximately 3 vol / g) at below 20° C. 7. Wash the acidified solution with n-heptane (1×10 vol / g). 8. Basify the aqueous phase to pH 8-9 (target pH 8.5) with 2M NaOH (approximately 3 vol / g) at below 20°C. 9. Back extract the aqueous phase with DCM (3×10 vol / g). 10. The combined DCM layers are dried over anhydrous Na2SO4 (2 g / g stage IV) and cycled three times through a plug of silica gel 60 (0.4 g / g). The plug is washed with DCM (2 x 2 vol / g). 11. Concentrate the solution under vacuum at 40° C. until the volume is reduced to approximately 10 mL / g. 12. Cool the solution to 0±5° C. (target 0° C.) and add 2M HCl in ether (1.5 eq.) dropwise at a rate that maintains the internal temperature at 0±5° C. (target 0° C.). 13. Stir the beige suspension for at least 1 hour at -0±5°C. 14. A solvent exchange with MTBE (20 vol / g) is performed by cooling the solution to 20±5° C. (target 20° C.) and slowly adding MTBE over 20-40 min (target 30 min). The solution is concentrated under vacuum below 40° C. until the volume is reduced to approximately 10 mL / g. 15. Repeat the solvent switch with MTBE (20 vol / g) until GC shows that the DCM content is below 3% w / w. 16. Granulate the resulting suspension at 20±5°C (target 20°C) for at least 1 hour. 17. The product is filtered, washed with MTBE (2×2.5 mL / g) and dried under vacuum at 55±5° C. to afford an off-white-yellow solid in 75% yield. 18. The product is crushed and further dried under vacuum at 55±5° C. to afford the compound of formula (1) as an off-white to yellow solid in 95% yield.
[0068] Example 2 - a) Initial Salt Screening Test The solubility of the compound of formula (1) was first qualitatively tested in 50 solvents. In all SAS experiments, the amorphous free base of the compound of formula (1) was obtained after evaporation of the experiment. The free base was very soluble or soluble in almost all solvents, with water being the only poor solvent.
[0069] Salt formation was investigated in a screen of 144 experiments. The screen was designed to include concentrations that were most suitable for aqueous intravenous formulation of the compound of formula (1). The screen used 12 solvents, 12 acids, and one molar ratio of base:acid of 1:1.05. Six monoprotic acids were used along with six di- or polyprotic acids. The 12 solvent systems used spanned most solvent classes and were as follows: HO, ethanol, 2-propanol, ethyl acetate, isobutyl acetate, acetone, methyl ethyl ketone, diethyl ether, acetonitrile, heptane, cumene, and DMSO.
[0070] Twelve counterions were used: formic acid, acetic acid, oxalic acid, citrate, tartaric acid, phosphoric acid, hydrochloric acid (37%, aqueous), hydrobromic acid (48%, aqueous), sulfuric acid (98%), methanesulfonic acid, p-toluenesulfonic acid, and ethane 1,2-disulfonic acid. Most experiments were performed in solution, except for those in water, which were performed as slurries, or those with citric acid, tartaric acid, p-toluenesulfonic acid, and 1,2-ethanedisulfonic acid.
[0071] In the case of the water experiments, most experiments yielded clear solutions after 72 hours of aging at room temperature. Some experiments showed slight turbidity, but no solids could be recovered. After 24 hours of cooling at 5° C., no solids were obtained. The experiments were finally evaporated at 60° C. and 10 mbar (1000 Pa) and the resulting solids were measured.
[0072] In the case of experiments with ethanol, 2-propanol, ethyl acetate, ethyl methyl ketone, diethyl ether, acetonitrile and heptane, a solid was obtained after aging at room temperature. If no precipitation occurred after aging for 72 h, the sample was first cooled to -20°C and, if no solid was obtained, exaporated at 30°C and 10 mbar (1000 Pa).
[0073] In the case of the cumene experiments, a solid was obtained after aging at room temperature. If no precipitation occurred after aging for 72 h, the sample was first cooled to -20°C and, if no solid was obtained, evaporated at 90°C and 10 mbar (1000 Pa).
[0074] In the case of the DMSO experiments, no solids were obtained after 48 hours of aging at room temperature. To each experiment, diethyl ether was added in a 10:1 ratio (2 mL) as an antisolvent for the salt. This did not result in any solids, so the solutions were left to cool at 5° C. overnight. In most cases, phase separation of a yellow viscous liquid was observed. Finally, the samples were evaporated at 30° C. and 100 mbar (10,000 Pa) for 24 hours to obtain solids, followed by evaporation at 90° C. and 10 mbar (1000 Pa) for 24 hours.
[0075] The following results were obtained:
[0076] Formic acid experiments: No XRD patterns were observed. All experiments resulted in amorphous material.
[0077] Acetic acid experiments: No XRD patterns were observed. All experiments resulted in amorphous material.
[0078] Oxalic acid experiment: Two patterns were obtained. Both patterns remained unchanged after stability testing. DSC analysis shows two thermal events, likely melting followed by decomposition at higher temperatures. HPLC purity was greater than 98%.
[0079] Citric acid experiment: Four patterns were obtained. After stabilization, almost all samples converted to a single pattern. TG and DSC analysis show that this form melts with decomposition compared to the free base, which showed no obvious thermal events. HPLC purity was 100%.
[0080] Tartaric acid experiment: Two patterns were obtained. All experiments converted to a single pattern after the stability experiment. TG analysis shows two thermal events: melting and immediate thermal decomposition. HPLC purity was 100%.
[0081] H3PO4 acid experiment: A pattern was obtained after stabilization. DSC analysis shows that two separate endothermic events occur, likely melting followed by decomposition at higher temperatures. HPLC purity was 100%.
[0082] HCl experiments: One pattern was obtained in 3 experiments. After stabilization, this pattern appeared in one more experiment. HPLC purity was >99%.
[0083] HBr experiments: Three patterns were obtained, all experiments yielded crystalline material. Only one of them converted to the other during the test. TG and DSC analysis show a clear melting event with no loss of mass. HPLC purity was >99%.
[0084] H2SO4 Experiments: One diffraction pattern was obtained in only one experiment. After stress testing, all experiments yielded amorphous material. DSC analysis showed an endothermic event at higher temperatures but was inconclusive. HPLC purity was greater than 99%.
[0085] Methanesulfonic acid experiments: One pattern was obtained in most experiments. This remained unchanged after stability testing except for one experiment where a new diffraction pattern was observed. DSC analysis showed no distinct thermal events compared to the free base, but multiple unassignable thermal events. HPLC purity was 100%.
[0086] p-Toluenesulfonic acid experiment: Three patterns were observed. After stabilization, all experiments converted to crystalline material and new diffraction patterns appeared. DSC analysis proved inconclusive due to small amounts of material. HPLC purity was >97%.
[0087] 1,2-Ethanedisulfonic acid experiment: Six patterns were obtained. After stress testing, most were converted to amorphous material with two exceptions. One of these two corresponds to a new diffraction pattern. DSC analysis shows a few endothermic events that can be assigned to either polymorphic transitions or melting events. HPLC purity was greater than 98%.
[0088] Initial conclusions - The salt screen highlighted the citrate, tosylate, tartrate, bromide, 1-2-ethanedisulfonate, hydrochloride and mesylate as the most suitable candidates for salt formation based on the following criteria: crystallinity (heavier weight) and polymorphic behavior, solubility and stability.
[0089] b) Second Salt Screening Test Based on the criteria of scale-up capability (higher yields and larger amounts), it was decided to further investigate the monohydrochloride, citrate and tartrate salts with respect to physicochemical characterization, preliminary stability and water solubility.
[0090] The results are summarized below.
[0091] All three salts could be obtained on multi-gram and kilogram scales.
[0092] The citrate salt was obtained in a second trial from ethyl acetate solvent at 25° C. and an acid:base molar ratio of 1.05:1. The salt precipitated after aging for 3 days. The XRPD pattern was consistent with that of "Citrate 1" identified during the initial salt screening. The first scale-up experiment resulted in a poorly crystalline material, which improved after exposure at 40° C. / 75% RH. A third scale-up experiment, performed under the same conditions as the second scale-up experiment, was successful in producing "Citrate 1".
[0093] The tartrate salt was obtained in the first trial from acetonitrile at an acid:base molar ratio of 1.05:1 after aging for 3 days. The pattern of the crystalline solid obtained in the first experiment corresponded to the "tartrate 2" pattern identified during the initial screening.
[0094] The monochloride salt was obtained in a third trial from diethyl ether in an acid:base molar ratio of 1.05:1 after aging for 3 days. The pattern of the crystalline solid obtained in the experiment corresponded to that of "Chloride 1" identified during the initial screening.
[0095] The first trial yielded a new crystalline form not detected during the salt screen, designated "Chloride 2." The second trial yielded an amorphous material that improved crystallinity after exposure to 40° C. / 75% RH ("Chloride 1").
[0096] The main properties and characteristics of the scaled-up salts are briefly presented in Table 1. "pH max" represents the pH at which the compound has maximum solubility "Smax". The temperatures of the decomposition / melting range and the presence of solvent molecules are estimated from thermal analysis. The risk of polymorphism was assessed based on the number of forms identified during this work and the reproducibility of the target pattern of the salt screening. [Table 1]
[0097] Conclusions of the second screening Concerning crystallinity - this could be achieved by precipitation. In the case of the citrate and chloride, the choice of solvent seems to be very important, since rapid evaporation of the solution yielded amorphous solids, when precipitation did not occur by aging of the experiments. The monochloride likely forms a hydrate or polymorph, and the tartrate probably has a new form, as recorded by XRPD in some of the disproportionation tests. All three salts show good thermal and solid state stability in the presence of ambient light, high temperature and high humidity for up to one week. The citrate salt degrades in 3% hydrogen peroxide (as concluded by HPLC).
[0098] As a general conclusion, all salts show both good properties and drawbacks. Of the three scaled-up salt combinations, the citrate and chloride are the most promising. The main drawback of the monochloride is the possibility of forming a hydrate, while the citrate showed degradation in oxidizing conditions and disproportionation at pH 4.5, which did not occur in the case of the chloride.
[0099] It was then envisaged to find out whether the di- and trihydrochloride salts of the compound of formula (1) could be produced and to proceed with testing to investigate the suitability of these new salt forms.
[0100] Example 3 – Preparation of the diHCl salt of the compound of formula (1) Approximately 2M (1.8-1.9M) hydrochloric acid in diethyl ether solution is slowly charged to the solution containing the free base of the compound of formula (1). The mixture is stirred and then warmed and tert-butyl methyl ether is slowly charged. The mixture is concentrated under slight vacuum to an approximate volume of 0.01 L / g of the compound of formula (1) and then cooled. The solvent exchange step with tert-butyl methyl ether is repeated until GC indicates that the dichloromethane content is s3% w / w. The resulting suspension is granulated and isolated by filtration, and each wet cake is washed with tert-butyl methyl ether. The diHCl salt is dried to constant weight in a vacuum oven to yield an off-white to yellow solid. The solid is then crushed and further dried to yield the final diHCl salt drug. [Table 2]
[0101] Characterization of the diHCl salt of the compound of formula (1) Elemental analysis was performed with reference standard 117621 with the following results: Observed contents: C 53.85%; H 5.11%; Cl 11.27%; N 9.03% Required amount: C 53.94%; H 4.85%; Cl 11.37%; N 8.99%
[0102] The data for batch 117621 is consistent with that theoretically expected for the diHCl salt of the compound of formula (1).
[0103] FT-IR - 2HCl salt of compound of formula (1) - see Figure 1. Mass Spectrometry - Mass spectrometry was performed with reference standard 117621 and the data is shown in FIG. X-ray Powder Diffraction (XRPD) and Differential Scanning Calorimetry (DSC) XRPD and DSC analysis show that the diHCl salt of the compound of formula (1) is amorphous (see Figures 7 and 8). Physicochemical characteristics A summary of the physicochemical characteristics of the diHCl salt of the compound of formula (1) is provided below.
[0104] Appearance: White to yellow powder Solubility: Very soluble in water (<0.2 mg / μL), highly soluble in ethanol (0.1-0.2 mg / μL), slightly soluble in 1-propanol and acetonitrile (0.01-0.03 mg / μL). Melting range: 120~124℃ pKa (free base): Estimated pKa1 = 7.54, pKa2 = 4.05; Calculated pKa1 = 7.07 Hygroscopicity (water yield at 90% RH): 3.2% pH: 2-3 (5 mg / mL solution in purified water) Polymorphism: Undetectable
[0105] Stability Data [Table 3]
Claims
1. Formula (1): [Formula 1] 1. A process for preparing the dihydrochloride salt of a compound of a) Formula (2): [Case 2] The compound of formula (3): [C3] Sequential treatment with o-tolylmagnesium chloride, N-methylpiperazine and iodine under conditions to give a compound of b) treating said compound of formula (3) from step a) with 3,5-bis(trifluoromethyl)benzyl bromide and a base under conditions to obtain a compound of formula (1); c) treating said compound of formula (1) with a solution of hydrochloric acid in diethyl ether under conditions to obtain the dihydrochloride salt of the compound of formula (1); A method comprising:
2. 2. The method of claim 1 , wherein step (a) is carried out in THF.
3. The method of claim 1, wherein formula (2) is added to 1M o-tolylmagnesium chloride in THF at 0° C.
4. The method of claim 1, wherein the N-methylpiperazine is added at 20° C.
5. The method according to claim 1, wherein 5M equivalents of N-methylpiperazine relative to formula (2) are added.
6. 10. The method of claim 1, wherein iodine is then reacted as a THF solution.
7. 2. The process of claim 1, wherein the base in step b) is potassium tert-butoxide.
8. 2. The method of claim 1, wherein 3,5-bis(trifluoromethyl)benzyl bromide is reacted with 1.2 molar equivalents of formula (3).
9. 10. The method of claim 1, wherein the compound of formula (3) is purified by solvent exchange prior to further reaction.
10. 2. The method of claim 1, wherein the compound of formula (1) is not isolated prior to conversion of the compound of formula (1) to a salt.
11. 2. The method of claim 1, wherein 5M equivalents of N-methylpiperazine relative to formula (2) are added at once.
12. 10. The method of claim 1, wherein iodine is then reacted in 1.5 molar equivalents at 0° C. under nitrogen as a THF solution.
13. 2. The process of claim 1, wherein the base in step b) is potassium tert-butoxide in an amount of 1.5 molar equivalents relative to formula (3).
14. 2. The process of claim 1, wherein the compound of formula (3) is purified by solvent exchange with MTBE prior to further reaction.
Citation Information
Patent Citations
4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
EP1035115A1
4-phenylpyridine derivative
JP2000247957A
Oral preparations and their uses
JP2021512869A
Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and recovery of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide by electrochemical methods
US20180244668A1
